As part of its Oyster strategy to advance non-core, early-stage assets, Bristol-Myers Squibb (BMS) has out-licensed regional rights to its investigational oncology compound BMS-777607 to Aslan Pharmaceuticals. Aslan will receive exclusive rights to develop and commercialise the drug candidate in China, Australia, Korea, Taiwan and other selected Asian countries while BMS retains rights in the rest of the world. Aslan will run and fund development of the drug under a pre-agreed programme to be carried out in Asia that will initially target gastric and lung cancers.